Infliximab and serious hematologic events

Phelan, Cynthia; Wooltorton, Eric
October 2004
CMAJ: Canadian Medical Association Journal;10/26/2004, Vol. 171 Issue 9, p1045
Academic Journal
Discusses the hematologic effects of the use of infliximab, a tumour necrosis factor antagonist, for the treatment of rheumatoid arthritis and Crohn's disease. Complications that may be caused by infliximab; Factors which led to the production of tumour necrosis factor by macrophages; Reactions resulting from infliximab intake.


Related Articles

  • Adalimumab/infliximab.  // Reactions Weekly;1/30/2010, Issue 1286, p7 

    The article describes the cases of 14 patients who developed lupus-like syndrome during treatment with adalimumab or infliximab for Crohn's disease (CD) or rheumatoid arthritis (RA). Anti-tumour necrosis factor (TNF)-α was discontinued in all patients. None of the patients experienced...

  • Etanercept/infliximab.  // Reactions Weekly;12/13/2008, Issue 1232, p17 

    The article describes a case of pulsating back pain in a 53-year-old man associated with tumor necrosis factor-alpha blockade while receiving infliximab for rheumatoid arthritis. It provides an overview of the medical history of the patient. It describes the back pain experienced by the patient....

  • Infliximab.  // Reactions Weekly;6/13/2009, Issue 1256, p19 

    The article describes the case of a man who developed drug-related symptoms after starting treatment with infliximab for Crohn's disease. The man developed arthralgia and swelling which affect his shoulders, knees ankles and spine, painless oral ulcers, facial rash, photosensitivity and fatigue,...

  • Infliximab.  // Reactions Weekly;2/14/2009, Issue 1239, p18 

    The article describes the case of a teenage boy who developed reversible posterior leukoencephalopathy syndrome after receiving infliximab to treat severe Crohn's disease. He had been hospitalised in a poor clinical state due to his severe disease and received dose of infliximab to which he...

  • Modelling the Time to Onset of Adverse Reactions with Parametric Survival Distributions. Maignen, François; Hauben, Manfred; Tsintis, Panos // Drug Safety;2010, Vol. 33 Issue 5, p417 

    Background: It has been postulated that the time to onset of adverse drug reactions is connected to the underlying pharmacological (or toxic) mechanism of adverse drug reactions whether the reaction is time dependent or not. Objective: We have conducted a preliminary study using the parametric...

  • Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease. Cohen, R. D.; Bowie, W. R.; Enns, R.; Flint, J.; Fitzgerald, J. M. // Thorax;Nov2007, Vol. 62 Issue 11, p1013 

    The use of anti-tumour necrosis factor (TNF) agents has expanded significantly over the past few years, particularly for rheumatological diseases and Crohn's disease. A number of associated opportunistic infections have been observed as a result of suppression of T cell-mediated immunity, the...

  • Adalimumab/infliximab.  // Reactions Weekly;7/26/2008, Issue 1212, p5 

    The article describes the case of a 69-year-old woman who developed non-small cell lung cancer (NSCLC) during anti-tumour necrosis factor (TNF) therapy with infliximab and adalimumab. The patient, who had Crohn's disease, was treated with infliximab, followed by maintenance adalimumab, from 2000...

  • Adalimumab/azathioprine/infliximab.  // Reactions Weekly;9/12/2009, Issue 1269, p5 

    The article describes the case of a 58-year-old man who developed T cell lymphoma after receiving azathioprine, infliximab and adalimumab for Crohn's disease. The patient presented with intermittent fever, low hemoglobin, anemia and Cushing's syndrome after 5.5 years of receiving azathioprine....

  • PSORÍASE INDUZIDA POR INFLIXIMAB. FERNANDES, Iolanda C.; TORRES, Tiago; SANCHES, Madalena; VELHO, Glória; LAGO, Paula; SELORES, Manuela // Acta Medica Portuguesa;SUP2011, Vol. 24 Issue S3, p709 

    Introduction: Recently, the tumor necrosis factor-a inhibitors (anti-TNF-a) have been extensively used in clinical practice, in the treatment of several immune-mediated disorders, such as inflammatory bowel diseases, rheumatoid arthritis and more recently in psoriasis. Case report: A 35-year-old...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics